New Zealand - engelsk - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - empagliflozin 5mg;  ; metformin hydrochloride 850mg;   - film coated tablet - 5mg/850mg - active: empagliflozin 5mg   metformin hydrochloride 850mg   excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry yellow 02b220010 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.

USA - engelsk - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - linagliptin (unii: 3x29zej4r2) (linagliptin - unii:3x29zej4r2), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - linagliptin 2.5 mg - jentadueto xr is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use jentadueto xr is not recommended in patients with type 1 diabetes mellitus. jentadueto xr has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using jentadueto xr [see warnings and precautions (5.2)]. jentadueto xr is contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73 m2 ) [see warnings and precautions (5.1)]. - acute or chronic metabolic acidosis, including diabetic ketoacidosis [see warnings and precautions (5.1)]. - hypersensitivity to linagliptin, metformin, or any of the excipients in jentadueto xr, reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred with linagliptin [see warnings and precautions (5.4) and adve

USA - engelsk - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u) - empagliflozin 10 mg - jardiance is indicated: - to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. - to reduce the risk of sustained decline in egfr, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. - to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. - as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. limitations of use jardiance is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. it may increase the risk of diabetic ketoacidosis in these patients [see warnings and precautions (5.1)] . jardiance is not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an egfr less than 30 ml/min/1.73 m2 . jardiance is likely to be ineffective in t

USA - engelsk - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u), linagliptin (unii: 3x29zej4r2) (linagliptin - unii:3x29zej4r2) - empagliflozin 10 mg - glyxambi is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see clinical studies (14.2)] . limitations of use glyxambi is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. it may increase the risk of diabetic ketoacidosis in these patients [see warnings and precautions (5.1)] . glyxambi has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using glyxambi [see warnings and precautions (5.2)]. glyxambi is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an egfr less than 30 ml/min/1.73 m2 . glyxambi is likely to be ineffecti

Israel - engelsk - Ministry of Health

boehringer ingelheim israel ltd. - ipratropium bromide - respirator solution - ipratropium bromide 0.25 mg/ml - ipratropium bromide - for the relief of symptoms of reversible bronchospasm associated with asthma, chronic bronchitis and emphysema . aerovent respirator solution is of particular benefit in relieving acute bronchospasm when used concomitantly with inhaled beta agonists.

Israel - engelsk - Ministry of Health

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - film coated tablets - linagliptin 2.5 mg; metformin hydrochloride 1000 mg - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajenta-duo should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta-duo has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta-duo.

Israel - engelsk - Ministry of Health

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - film coated tablets - metformin hydrochloride 850 mg; linagliptin 2.5 mg - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajenta-duo should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta-duo has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta-duo.

Singapore - engelsk - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - afatinib dimaleate 29.5600mg eqv afatinib - tablet, film coated - 20.0000mg - afatinib dimaleate 29.5600mg eqv afatinib 20.0000mg

Singapore - engelsk - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - afatinib dimaleate 44.3400mg eqv afatinib - tablet, film coated - 30.0000mg - afatinib dimaleate 44.3400mg eqv afatinib 30.0000mg

Singapore - engelsk - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - afatinib dimaleate 59.1200mg eqv afatinib - tablet, film coated - 40.0000mg - afatinib dimaleate 59.1200mg eqv afatinib 40.0000mg